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Elevated expression of FoxM1 in breast cancer
correlates with an undifferentiated tumor phenotype
and a negative clinical outcome. However, a role
for FoxM1 in regulating mammary differentiation
was not known. Here, we identify another function
of FoxM1, the ability to act as a transcriptional
repressor, which plays an important role in regulating
the differentiation of luminal epithelial progenitors.
Regeneration of mammary glands with elevated
levels of FoxM1 leads to aberrant ductal morphology
and expansion of the luminal progenitor pool.
Conversely, knockdown of FoxM1 results in a shift
toward the differentiated state. FoxM1 mediates
these effects by repressing the key regulator of
luminal differentiation, GATA-3. Through association
with DNMT3b, FoxM1 promotes methylation of the
GATA-3 promoter in an Rb-dependent manner. This
study identifies FoxM1 as a critical regulator of
mammary differentiationwith significant implications
for the development of aggressive breast cancers.
INTRODUCTION
The mammary gland is a dynamic organ that undergoes con-
tinuous cycles of proliferation, differentiation, and apoptosis.
During puberty, the rudimentary mammary gland invades the
surrounding fat pad and undergoes extensive growth resulting
in ductal expansion and formation of a mature branched
mammary structure. In early pregnancy, the gland undergoes
further growth and tertiary branching to create alveoli or bud-
like structures to support milk production. Throughout preg-
nancy, the epithelium continues to proliferate. After weaning,
widespread apoptosis and angiogenic remodeling result in rees-
tablishment of the mature gland (Hennighausen and Robinson,
2005). This cellular plasticity is attributed to a stem cell popula-
tion (Kordon and Smith, 1998). Studies show that all of the
mature cell types of the mammary gland can be produced
from a single progenitor (Stingl et al., 2006; Shackleton et al.,
2006). A pool of pluripotent stem cells in the mammary glandgives rise to lineage restricted progenitor cells that can be further
differentiated into mature luminal or myoepithelial cells (Vis-
vader, 2009).
A clear understanding of mammary stem/progenitor regula-
tion and the process by which these cells become fully differen-
tiated has significant implications in the field of breast cancer.
Mammary tumors contain a small subset of cancer stem cells
with tumorigenic potential (Al-Hajj et al., 2003). Breast tumors
with a ‘‘stem-like’’ signature are associated with a drug resis-
tant phenotype, high metastatic potential, and poor patient
outcome (Ginestier et al., 2007; Creighton et al., 2009).
Conversely, well-differentiated or low-grade tumors carry
a more favorable prognosis (Elston and Ellis, 1991). While the
exact relationship between normal mammary stem cells and
tumor stem cells is not known, several tumor suppressors
and oncogenes have been identified as key regulators of
normal mammary differentiation indicating an overlap in their
regulatory mechanisms (Wiseman and Werb, 2002; Siegel and
Muller, 2010).
The zinc finger transcription factor GATA-3 is required for
proper mammary gland development as well as maintenance
of mature luminal cells (Kouros-Mehr et al., 2006; Asselin-
Labat et al., 2007). GATA-3 is highly correlated with estrogen
receptor expression and is a predictor of positive patient
outcome (Yoon et al., 2010). Observations in human tumors
have shown that as tumor grade increases, GATA-3 expression
is silenced by several mechanisms including DNA methylation
(Yan et al., 2000). Overexpression of GATA-3 in tumors led
to significant reductions in tumor grade and metastasis in
mouse models (Dydensborg et al., 2009; Kouros-Mehr et al.,
2008). Insight into the regulation of GATA-3 expression and
activity could have considerable value in designing novel
therapeutics.
FoxM1 is a member of the winged helix family of transcrip-
tion factors whose expression is elevated in all tumor types
examined (Pilarsky et al., 2004). Expression and transcriptional
activity of FoxM1 are tightly regulated during cell cycle (Major
et al., 2004). The transcriptional activity of FoxM1 is dependent
on phosphorylations by cell cycle regulated kinases (Fu et al.,
2008; Chen et al., 2009). Target genes include key components
of the cell cycle, required for transition to S-phase and
successful entry and completion of mitosis (Wang et al.,
2005). Aberrant expression of FoxM1 leads to increased tumorCell Reports 1, 715–729, June 28, 2012 ª2012 The Authors 715
Figure 1. FoxM1 Expression in Tumor and Normal Tissue
(A) Oncomine, a publicly available microarray database was used to analyze FoxM1 expression in 200 samples of invasive ductal carcinoma. Samples were
organized by grade and fold-change of FoxM1 RNA from normal was graphed using a box plot *p < 106.
(B) Representative immunohistochemistry of FoxM1 in normal mammary tissue as well as, grade 1, grade 2, and grade 3 breast carcinomas are shown. Scale bar
represents 10 mm.
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growth, invasion, and metastasis (Park et al., 2011; Wang et al.,
2007).
FoxM1 expression is elevated in mammary tumors (Wonsey
and Follettie, 2005). In a study of human breast cancer samples,
FoxM1 overexpression was identified as an indicator of poor
patient outcome. Moreover, it was observed that FoxM1
expression showed a stepwise increase with each tumor grade
(Bektas et al., 2008). In this study, we provide evidence that
FoxM1 is a negative regulator of GATA-3. We demonstrate
that FoxM1 is a critical regulator of mammary progenitor cells
and luminal cell fate through direct transcriptional repression
of GATA-3.
RESULTS
Characterization of FoxM1 Expression in Breast Cancer
and Mammary Development
Tumor grade and patient outcome are inversely correlated (El-
ston and Ellis, 1991). Analysis of publicly available microarray
data (Oncomine) demonstrates that the expression of FoxM1
increases with tumor grade in human breast cancers (Figures
1A and S1A). This pattern was further validated using tissue
arrays, confirming that FoxM1 expression is inversely correlated
with tumor differentiation (Figures 1B and S1B). From this
analysis, we hypothesized that FoxM1 may negatively regulate
mammary differentiation. To investigate this, we examined the
normal pattern of expression throughout the key stages of post-
natal mammary development. Pregnancy, a period of ductal
growth and expansion, showed high levels that steadily
decreased through days 1, 5, and 10 of lactation, while involu-
tion, characterized by apoptosis and remodeling, exhibited the
lowest expression (Figure 1C). This pattern was also reflected
at the protein level by immunohistochemistry (Figure 1D).
Mammary terminal end buds, present during puberty, are of
particular significance because the cap cells or those found in
the invading front compose the progenitor cell population.
Strong nuclear staining for FoxM1 was observed in the cap
and progenitor cells (Figure 1D, top left). At all stages of devel-
opment, FoxM1 expression was primarily found in cells of
luminal lineage. To confirm this observation, we used in situ
hybridization to identify FoxM1mRNA followed by immunostain-
ing for luminal and myoepithelial cell types. There was a clear
overlap of antisense probe hybridization and cytokeratin 18
staining indicating FoxM1 is expressed mainly in luminal cells
(Figure S1C).
The timing and pattern of expression suggests that FoxM1
levels are higher in cells that are less differentiated. Previously
defined flow cytometry markers were used to separate
mammary stem cells (CD29hi), luminal progenitors (CD29lo,
CD61+), and differentiated luminal cells (CD29lo, CD61) (Stingl(C) Levels of FoxM1 RNA were determined by semiquantitative RT-PCR. All sam
stages: 5 weeks (puberty), 8 weeks (virgin adult), P6, P18 (early and late pregnan
each stage.
(D) Glands from each stage were sectioned and stained for FoxM1 expression u
(E) Mammary glands from 8-week-old C57BL/6 mice were digested and stained
were sorted. Cytokeratin 18, smooth muscle actin, and c-kit were used to assess t
and FoxM1. Data are normalized to the stem cell population *p < 104 **p < 0.05et al., 2006; Shackleton et al., 2006; Asselin-Labat et al., 2007).
Sorted RNA from C57BL/6 mice was analyzed for FoxM1
expression using quantitative RT-PCR. The level of FoxM1 in
stem cells was 10-fold higher than differentiated cells, while
luminal progenitors showed a nearly 50-fold increase. Expres-
sion of cytokeratin 18, c-kit, and smooth muscle actin were
used to determine the purity of luminal, luminal progenitors
and myoepithelial populations, respectively (Figure 1E, Lim
et al., 2009). Taken together, these results demonstrate that
FoxM1 expression is highest in luminal progenitor cells and
decreases upon differentiation.
Loss of FoxM1 Leads to a Delay in Lobuloalveolar
Development during Pregnancy
In order to examine the role of FoxM1 at key stages of
mammary development, we utilized the previously established
WAP-Cre system (Wagner et al., 1997). Mice expressing
WAP-Cre were crossed with mice harboring the FoxM1 gene
flanked by LoxP sites (FoxM1 FL/FL). This system allows dele-
tion of FoxM1 in epithelial cells as they differentiate during
pregnancy. During the second pregnancy, we examined
mammary glands at the following time points: 8 weeks (virgin),
pregnancy day 6 (early pregnancy), pregnancy day 18 (late
pregnancy), lactation days 1, 5, 10, and involution day 6 (Fig-
ure 2A). During early stages of pregnancy, the mammary
epithelium expands and begins to form lobuloalveolar units
(Hennighausen and Robinson, 2005). These structures were
clearly seen in wild-type mice at pregnancy day 6 but, none
of the FoxM1 FL/FL mice developed lobuloalveolar structures.
The pregnancy day 6 glands in the FoxM1 FL/FL mice ap-
peared similar to those of 8-week virgin controls (Figures 2A
and 2B). These glands failed to form appreciable alveoli as evi-
denced in whole-mount analysis (Figure 2B). At pregnancy day
18 however, alveoli were clearly visible, albeit in reduced
number, indicating a delay in aleveolar differentiation in the
FoxM1 FL/FL mice.
Lactating glands in FoxM1 FL/FL mice were histologically
different from those of wild-type mice. FoxM1 FL/FL glands
appeared flattened and the number of milk globules in the
alveoli was reduced compared to those of wild-type (Fig-
ure 2A). Pups from the FoxM1 FL/FL mice survived and did
not differ in weight in comparison to pups born to control
mice indicating FL/FL mice were able to produce sufficient
milk to support their litters (data not shown). Western blot
of key milk proteins showed a delay in accumulation of both
a and b-casein in FL/FL mice during pregnancy. Yet, on lacta-
tion day 1, FoxM1 FL/FL mice and WT mice showed equivalent
expression of milk proteins (Figure 2C). This observation
was supported by immunohistochemical staining for the milk
proteins (Figure 2D). Taken together, these data suggestples were collected from inguinal mammary glands at various developmental
cy), L1, L5, 10 (lactation), and I6 (involution). Four to seven mice were used for
sing DAB and hematoxylin counterstain.
for CD24, CD29, and CD61. Stem cells, luminal progenitors, and luminal cells
he purity of the populations. RT-PCR shows relative expression of CK18, SMA,
.
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Figure 2. FoxM1 Loss Results in Defects in Mammary Development during Pregnancy
(A) H&E staining of mammary gland sections from each time point is shown. Control glands expressing only WAP-Cre are shown on the left, and glands
lacking FoxM1 are shown in adjacent panels. A lower magnification of pregnancy day 6 glands is shown to better demonstrate details. Scale bar represents
10 mM.
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that the loss of FoxM1 leads to a delay in lobuloalveolar
differentiation.
Acute Loss of FoxM1 Results in an Increase in
Differentiated Luminal Cells
To determine whether FoxM1 acts as a regulator of luminal cell
differentiation in virgin mice, we analyzed the consequences of
FoxM1 deletion in mammary tissue using the WAP-rtTA-Cre
deletion system. Unlike the WAP-Cre system, the WAP-rtTA
system allows for deletion in non-pregnant mice (Kouros-Mehr
et al., 2006). FoxM1 FL/+ and FL/FL littermates, expressing the
inducible Cre, were given doxycycline in their drinking water
for 5 or 15 days. After 5 days of treatment, we observed an
80% reduction of FoxM1 in luminal progenitors and 90% in
differentiated luminal cells while stem cells did not show a sig-
nificant reduction (Figure 3A).
After 15 days of doxycycline, FoxM1 protein was undetectable
by immunostaining (Figure 3C). Whole-mount staining using
carmine alum showed that FoxM1 FL/FL, WAP-rtTA-Cre mice
had narrow ductal branching, whereas the FoxM1 FL/+ mice
appeared identical to wild-type mice (Figure 3B). Quantification
of the number of branches showed no difference between
FL/+ and FL/FL glands (Figure S2A). On closer examination of
the recombinant glands by sectioning, FoxM1 FL/FL mice ex-
hibited abnormal histological staining by H&E. Glands were not
composed of a single layer of epithelial cells and lumens were
filled with cells that expanded beyond the myoepithelial layer.
The rates of proliferation and apoptosis were similar between
both genotypes (Figures S2B and S2C). Staining of cytokeratin
18 and estrogen receptor alpha indicated that the cells were
mature luminal epithelium, suggesting an expansion of the
differentiated pool (Figure 3C).
Stem, progenitor, and differentiated pools were analyzed after
15 days of treatment to examine the effects of FoxM1 deletion
on mammary cell subtypes. There was an approximate 20%
increase in differentiated luminal cells with a concomitant loss
in stem and progenitor populations demonstrating that loss of
FoxM1 in the mammary gland resulted in a shift toward the
differentiated state (Figure 3D). Interestingly, the stem cell popu-
lation was affected by the loss of FoxM1, yet FoxM1 was not
deleted in this population. The effect on the stem cell pool was
likely secondary to changes in the differentiated cell population
as it has been shown that the stem cell pool is regulated through
hormonally mediated paracrine signaling by differentiated
luminal cells (Asselin-Labat et al., 2010; Joshi et al., 2010).
Consistent with the observation that FoxM1 loss leads to a shift
toward the differentiated state, deletion resulted in an increase
in markers of luminal differentiation, including estrogen receptor
alpha, amphiregulin, cytokeratin 18, and cadherin 11 (Figure 3E).
Taken together, these data demonstrate that loss of FoxM1 in
the adult gland leads to an increase in differentiated cells and
a loss of progenitor pools.(B) Representative carmine alum whole-mount analysis of mice expressing W
magnification are shown in black and white to increase the clarity. Four to eight
(C) Western blot of FoxM1, a-Casein, and b-Casein are shown. a-tubulin is prov
(D) Immunohistochemistry using an antibody against mouse milk is shown in the
See also Figure S2.Increased Expression of FoxM1 Inhibits Luminal
Differentiation
In order to explore the consequences of high levels of FoxM1 on
mammary differentiation, we regenerated the mouse mammary
gland with elevated expression of FoxM1. We took advantage
of previous work involving mammospheres, an ex vivo system
of culturing mammary stem and progenitor cells (Dontu et al.,
2003). These mammospheres can be genetically manipulated
by viruses and subsequently implanted into the cleared fat
pad of 3- to 4-week-old prepubescent mice. After 7–8 weeks,
manipulated cells repopulate the entire gland (Deome et al.,
1959; Liao et al., 2007). In our case, elevated FoxM1 could be
detected in all cell types derived from the mammary stem cells
(data not shown).
Mammary epithelial cells were obtained from 6- to 8-week-old
mice, infected with retrovirus expressing either GFP or GFP-
FoxM1 and then allowed to form spheres. GFP-positive mam-
mosphere cells were identified by sorting and injected into the
cleared fat pads of 3-4 week old mice. GFP and GFP-FoxM1
positive cells were placed on contralateral sides of the same
animal, allowing each animal to function as their own control
(Figure 4A). On whole-mount analysis, GFP-FoxM1 glands
showed narrowing in comparison to theirGFP counterparts (Fig-
ure 4B). Regenerated glands were sectioned and stained to
analyze the architecture of individual ducts.GFP glands showed
the expected staining pattern while FoxM1 expressing glands
showed distinct hyperplastic regions of excessive cell infiltration,
epithelial cells were filling the lumen or spreading beyond the
basal layer (Figures 4C and S8).
To further investigate the altered architecture of FoxM1 ex-
pressing glands, sections were analyzed using immunohisto-
chemistry. Staining with the basal marker, smooth muscle actin
(SMA) revealed a startling phenotype. As expected, GFP glands
contained a layer of SMA positive cells surrounding luminal cells
while FoxM1 expressing glands contained the expected pattern
as well as SMA positive cells surrounded by luminal cells (Fig-
ure 4C). This phenotype was previously observed in glands ex-
pressing shRNA to Cbf-1, a notch cofactor and was correlated
with an expansion of undifferentiated mammary cells (Bouras
et al., 2008). Of note, these cells did not stain positive with
the basal marker p63, indicating that they were not misplaced
myoepithelial cells (Figure S2D). Additionally, these changes
could not be attributed to the ability of FoxM1 to regulate prolif-
eration or apoptosis as there were no differences in markers for
either (Figures S2E and S2F).
Cytokeratin 18 staining shows a uniform luminal restricted
staining pattern (Hennighausen and Robinson, 2005). The GFP
glands exhibited this typical staining pattern, while the FoxM1
glands showed a punctate pattern distinct from differentiated
luminal cells. The expanded cells did not stain positive for
estrogen receptor alpha, indicating the expansion of an undiffer-
entiated cell of luminal origin. This notion is further supported byAP-Cre and either wild-type FoxM1 or FoxM1 FL/FL. Pictures taken at 3x
mice from both genotypes were analyzed at every stage.
ided as a loading control.
lower panel. Staining is done using DAB with a hematoxylin counterstain.
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Figure 3. FoxM1 Deletion Leads to an Expansion of Differentiated Luminal Cells
(A) Four 8- week-oldWAP-rtTA-Cre and FoxM1 FL/FL,WAP-rTA-Cremicewere treatedwith doxycycline (2mg/ml) in their drinkingwater for 5 days. Stem, luminal
progenitor, and luminal cells were sorted and FoxM1 expression was analyzed by RT-PCR *p < 0.01 **p < 103.
(B) Whole mount of inguinal mammary glands 15 days after doxycycline treatment were visualized with carmine alum stain. Higher magnification (33) is shown
with lower magnification in the inset (13). Images are shown in black and white in order to increase the clarity.
(C) Hematoxylin and eosin staining as well as immunohistochemistry of FoxM1, cytokeratin 18, estrogen receptor alpha, and milk are shown after 15 days of
treatment. Scale bar represents 10 mm.
(D) Flow cytometry analysis of stem cells, luminal progenitors, and differentiated luminal cells. The plots show CD29 and CD61 expression of cells that stained
positive for CD24. Percentage of each cell type for both genotypes is shown below *p < 0.04 **p < 0.05 ***p < 0.03.
(E) RT-PCR of estrogen receptor alpha, amphiregulin, cytokeratin 18, and cadherin 11 are shown normalized to 18 s RNA *p < 103, **p < 0.05, ***p < 0.01.
See also Figure S2.
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Figure 4. Overexpression of FoxM1 in Mammary Gland Results in an Expansion of Progenitors and a Loss of Differentiation Markers
(A) Schematic representation of experimental design.
(B) GFP whole-mount imaging of mammary glands. Boxed areas are shown in the inset at lower magnification.
(C) Hematoxylin and eosin and immunohistochemistry of GFP and FoxM1-GFP glands. Smooth muscle actin, cytokeratin 18, and estrogen receptor alpha
immunostaining is shown. Arrows in SMA section are showing displaced SMA+ cells surrounded by luminal cells. Representative sections from six mice
are shown. Scale bar represents 10 mm.
(D) CD61 immunohistochemistry is shown. Enlarged images of GFP and GFP-FoxM1 mice are displayed in the right panel. Arrowhead shows a cluster of
CD61+ cells.
(E) Analysis of mammary stem cells, luminal progenitor, and luminal cell pools was performed in GFP or FoxM1-GFP expressing mice. Glands were digested
to generate single cell suspensions, stained, and examined by flow cytometry. Representative dot plots of CD24+ cells are shown with percentages listed in
each box. The bottom panel provides quantification from four mice. The percentage of each population is shown relative to the GFP control in the same animal
*p < 0.03 **p < 0.01 ***p < 0.001.
(F) RT-PCR analysis of GFP and GFP-FoxM1 glands for expression of estrogen receptor alpha, cytokeratin 18, amphiregulin, and cadherin 11. *p < 104
**p < 0.001 ***p < 0.05.
See also Figure S3.
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Figure 5. FoxM1 Is a Negative Regulator of GATA-3 In Vivo
(A) Western blot analysis of FoxM1 and GATA-3 protein levels in WAP-rtTA-Cre, FoxM1 FL/+ (control) and WAP-rtTA-Cre, FoxM1 FL/FL as well as GFP (control)
and GFP-FoxM1 expressing animals are shown in the top panel. Alpha tubulin is shown as a loading control. RT-PCR expression of glands is shown below,
GATA-3 expression is normalized to 18S RNA. *p < 0.05, **p < 106.
(B) Immunohistochemical staining of GATA-3 expression using DAB and hematoxylin counterstain.
(C) Binding of FoxM1 to the promoter of GATA-3 was analyzed using an in vivo ChIP experiment. FoxM1 antibody was used to immunoprecipitate FoxM1 in
glands of C57BL/6 mice. RT-PCR was used for three different regions of the GATA-3 promoter that have putative FoxM1 binding sites. Graph displays relative
binding over an IgG control *p < 105 **p < 0.003 ***p < 0.001.
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staining for CD61, a marker of luminal progenitors. Glands ex-
pressing FoxM1 exhibited an increased number and intensity
of CD61 positive cells as compared to control glands (Figure 4D).
To confirm the expansion of an undifferentiated cell type in
FoxM1 expressing glands, we analyzed cell populations using
flow cytometry. Comparing FoxM1 to paired GFP controls
showed a distinct shift away from the differentiated state. The
luminal progenitor pool expanded considerably, approximately
20%, with a similar reduction in the percentage of differentiated
cells, suggesting that addition of FoxM1 resulted in a failure of
cells to properly exit the luminal progenitor pool and differentiate
fully (Figure 4E). Consistent with this notion, RT-PCR data
showed a reduction in estrogen receptor alpha, amphiregulin,
cytokeratin 18, and cadherin 11, markers of luminal differentia-
tion (Figure 4F).
FoxM1 Is a Negative Regulator of GATA-3 In Vivo
The hyperplastic phenotype has been previously observed
after acute loss of GATA-3 in the mammary gland (Kouros-
Mehr et al., 2006). GATA-3 has been shown to be a key regulator
of luminal differentiation and a tumor suppressor (Asselin-Labat
et al., 2007; Dydensborg et al., 2009; Yoon et al., 2010). We
hypothesize that FoxM1 functions as a negative regulator of
GATA-3. Glands in which FoxM1 was deleted showed a consid-
erable increase in GATA-3 RNA and protein levels by western
blot and RT-PCR, respectively. Conversely, the RNA and protein
level of GATA-3 was significantly decreased in GFP-FoxM1 ex-
pressing glands compared to GFP counterparts (Figure 5A).
Sorted luminal progenitors from both overexpression and
knockdown mice also exhibited evidence that FoxM1 regulates
GATA-3 in the progenitor population (Figure S3A). GATA-3
immunostaining generally shows a pattern of strong nuclear
staining in luminal cells that was evident in control glands.
FoxM1 deletion resulted in an increased staining intensity while
overexpression resulted in a decreased and diffuse staining
pattern for GATA-3 (Figure 5B).
The mouse promoter of GATA-3 contains three FoxM1
consensus sequences within 2 kb of the transcriptional start
site. In vivo chromatin immunoprecipitation (ChIP) assay showed
that endogenous FoxM1 was bound to all of these sites in the
mammary gland (Figure 5C). Taken together, the data indicate
that FoxM1 is able to bind and repress transcription of GATA-3
in vivo.
We then sought to determine whether the inhibition of
mammary luminal differentiation by FoxM1 was linked to the
repression of GATA-3. To investigate this, we coexpressed
GATA-3 along with FoxM1 in mammary stem cells using retrovi-
ruses. The reconstituted glands were harvested and the
cell populations were analyzed by sorting. Coexpression of
GATA-3 reversed the defects observed in FoxM1 expressing(D) Graph summarizing flow cytometry data from control, GATA-3, FoxM1, and Fo
of each cell type is graphed. p values are calculated as compared to control an
expression is shown in graphs to the right.
(E) Flow cytometry analysis of glands regenerated with either WT or FoxM1 FL/FL
were fed doxycyline for 14 days following the surgery. Glands were analyzed a
significant. *p < 0.05, **p < 0.001, ***p < 0.01. Semiquantitative RT-PCR of FoxM
See also Figure S3.mammary glands (Figure 5D). Immunohistochemistry showed
that glands expressing both FoxM1 and GATA-3 had visible
lumens and no extensive cellular hyperplasia. In addition,
expression of markers of differentiated cells was also corrected
(Figure S3B). While GATA-3 expression reversed the effects of
FoxM1 on luminal differentiation, it alone had no detectable
effect on increasing the luminal differentiation, suggesting that
the level of GATA-3 overexpression, in our experiments was
insufficient to drive luminal differentiation. GATA-3 expression
had little effect on the stem cell population. We suspect that
FoxM1 increases stem cells independently of GATA-3 because,
in other systems, FoxM1 has been shown to stimulate expres-
sion of the ‘‘stemness genes’’ (Wang et al., 2011).
In order to confirm the role of GATA-3-regulation in FoxM1-
mediated inhibition of luminal differentiation, we analyzed the
effect of GATA-3 depletion in FoxM1-depleted glands. Infection
of mammospheres formed from FoxM1 FL/FL and WT WAP-
rtTA-Cre mice with either control or GATA-3 targeting shRNA
allowed for regeneration of glands that lacked both FoxM1 and
GATA-3. Analysis of these glands by flow cytometry demon-
strated that knockdown of GATA-3 was sufficient to reverse
the loss of luminal progenitors and expansion of differentiated
cells observed in mice after loss of FoxM1 (Figure 5E). Histolog-
ically, the FoxM1 knockdown phenotype was reversed by
knockdown of GATA-3 (Figure S4A). These observations
suggest that repression of GATA-3 is the dominant mechanism
by which FoxM1 inhibits differentiation of mammary progenitors.
FoxM1 Promotes GATA-3 Methylation
in an Rb-Dependent Manner
Given the observations in mouse studies that FoxM1 inhibits
GATA-3, we expect to see an inverse correlation between
GATA-3 and FoxM1 expression in human breast tumor samples.
Consistent with that, analyses of publicly available database
reveals an opposite expression pattern of FoxM1 and GATA-3
(Figure 6A). FoxM1 binding sites are conserved across the
mammalian genome (Figure S5A). The mouse and human
GATA-3 promoters contain three FoxM1 consensus sites within
2 kb of the start site. We confirmed the direct binding of FoxM1
to the human GATA-3 promoter, indicating that FoxM1 can
regulate GATA-3 transcriptional levels in human breast cancer
cells. Additionally, treatment of MDA-MB-453 cells with siRNA
to FoxM1 resulted in a reduction in binding, demonstrating
the specificity of the assay (Figure 6B). Previous studies
showed that the promoter of GATA-3 could be targeted for
DNA methylation during tumor progression (Yan et al., 2000).
We hypothesized that the repression by FoxM1 may be
methylation dependent therefore, we measured the ability of
FoxM1 to inhibit GATA-3 in the presence of the methyltransfer-
ase inhibitor, 50azacytidine (50AZA). Addition of 50AZA ablatedxM1-GATA-3 expressing mice. Each group contains four mice and percentage
imals *p < 0.05, **p < 0.01. Semiquantitative RT-PCR of GATA-3 and FoxM1
, WAP-tTA-Cre, and either shRNA control or GATA-3 targeting shRNA. All mice
fter 8 weeks. Data collected from five mice are shown in the graph. N.S., not
1 and GATA-3 expression is shown in graphs to the right. See also Figure S4.
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Figure 6. FoxM1 Transcriptional Repression of GATA-3 Is Methylation Dependent
(A) FoxM1 and GATA-3 expression in human breast cancers. Fold change from normal is graphed. Heat map of individual samples is shown above the graphs
*p < 103 **p < 105 ***p < 1011.
(B) MDA-MB-453 ells were treated with either control or FoxM1 targeting siRNA. Chromatin immunopreciptation assay of FoxM1 binding to the GATA-3 promoter
was performed. Quantitative PCR results are shown *p < 0.01.
(C) FoxM1 was transfected into MDA-MB-453 cells and 4 hr later, either vehicle (PBS) or 1 mMof 50azacytidine was added to each plate. Samples were collected
48 hr later and RT-PCR of GATA-3 expression is shown as normalized to GAPDH *p < 0.01.
(D) Cells were collected and immunopreciption was performed using DNMT3b antibody; western blot of FoxM1 is shown.
(E) Seventy-two hours after transfection with control siRNA or FoxM1 targeting siRNA, cells were fixed and chromatin immunoprecipitated (ChIP) with DNMT3b
antibody or IgG was performed. Relative binding of DNMT3b to the GATA-3 promoter sites are graphed. Samples have been normalized to IgG and relative
binding is shown *p < 0.01, **p < 0.05.
See also Figure S6.the repression of GATA-3 after FoxM1 overexpression, demon-
strating that repression is methylation dependent (Figure 6C).
DNMT3b has been specifically implicated in mammary tumor724 Cell Reports 1, 715–729, June 28, 2012 ª2012 The Authorsbiology. It was shown to be responsible for the hypermethylated
phenotype and subsequent decrease in expression of tumor
suppressor genes in breast cancer (Roll et al., 2008). We
explored the possibility that FoxM1 could function in a complex
with DNMT3b and target the GATA-3 promoter for methylation.
We observed that FoxM1 coimmunoprecipitated with DNMT3b
(Figure 6D). Moreover, in the presence of control siRNA, binding
of DNMT3b was detected by ChIP in the regions of the GATA-3
promoter that contained FoxM1 binding sites. The binding was
significantly decreased when cells were treated with siRNA to
FoxM1, indicating that DNMT3b binds to the GATA-3 promoter
in a FoxM1 dependent manner (Figure 6E).
Previous studies have shown that the tumor suppressor Rb
could bind FoxM1 (Major et al., 2004; Wierstra and Alves,
2006). We confirmed this binding in breast cancer cells. In addi-
tion, we demonstrate that DNMT3b and Rb are present in
a complex (Figure S6A). Therefore, we investigated whether
FoxM1 requires Rb for inhibition of GATA-3 transcription. We
utilized a doxycycline inducible shRNA system to silence Rb
(Figures S6B and S6C). In the absence of Rb, expression of
FoxM1 failed to repressGATA-3 and in fact led to a considerable
increase (Figure 7A). It is likely that FoxM1 binds the GATA-3
promoter and in the absence of Rb, the repressor complex
cannot form and FoxM1 functions as an activator. ChIP experi-
ments using control siRNA or siRNA specific to FoxM1 showed
that Rb could not bind to the GATA-3 promoter in the absence
of FoxM1 (Figure 7B).
In order to functionally test this model, we analyzed the meth-
ylation status of the GATA-3 promoter using methylation-
specific PCR. Expression of FoxM1 led to a considerable
increase inmethylation ofGATA-3 compared to control. Interest-
ingly, the increase was ablated in the absence of Rb (Figures 7C
and S7B), demonstrating that the methylation and subsequent
repression of GATA-3 was Rb-dependent. We investigated
whether knockdown of Rb in vivo could ablate the FoxM1 medi-
ated inhibition of differentiation. Therefore, we regenerated
mouse mammary glands expressing scrambled shRNA or
shRNA targeting Rb in the presence and absence of FoxM1.
Sorting experiments demonstrated that expression of FoxM1
led to an inhibition of differentiation that was alleviated by the
knockdown of Rb (Figure 7D). Taken together, the data support
a model in which FoxM1 functions in a complex with DNMT3b
and Rb to inhibit GATA-3 expression and, in effect, mammary
luminal differentiation.
DISCUSSION
In this study, we have assigned another regulatory role to FoxM1,
prevention of the terminal differentiation of mammary luminal
progenitor cells through repression of GATA-3. It has been
previously shown that GATA-3 maintains the differentiated state
of the gland by activating a network of genes required for the
transition from the progenitor to the differentiated state
(Kouros-Mehr et al., 2006; Asselin-Labat et al., 2007). Consistent
with that, we find that FoxM1 binds to and transcriptionally
represses GATA-3 expression, resulting in a failure of cells to
activate this transcriptional program. This study provides insight
into the regulation of GATA-3 and identifies FoxM1 as a factor
required to maintain the mammary luminal progenitor pool.
An additional and unexpected finding in this study is that the
repression of GATA-3 by FoxM1 relies on the retinoblastoma(Rb) protein. While previous reports showed that Rb and
FoxM1 are interacting partners, a functional effect of this binding
has not been reported (Major et al., 2004; Wierstra and Alves,
2006). Here, we show that this interaction is required for the
repression of GATA-3 in the mammary gland. The involvement
of Rb in this process is of particular interest because Rb is
generally thought to promote tissue differentiation (Sherr and
McCormick, 2002). Our studies indicate the converse is true
with regard to mammary luminal differentiation. Inhibition of
differentiation by Rb is not unfounded. Previous in vitro and
in vivo studies indicate a repressive role of Rb in adipogenic
differentiation (Fajas et al., 2002a; Calo et al., 2010). Rb binds
to E2F4 to inhibit expression of PPAR-g, a master regulator of
adipogenic differentiation (Fajas et al., 2002a, 2002b). This is
similar to our observation in that Rb binds to FoxM1 to inhibit
expression of GATA-3, a master regulator of mammary luminal
differentiation.
At this time, we cannot exclude the possibility that repression
of GATA-3 by Rb may promote the differentiation of another cell
type. We did not find immunohistochemical or flow cytometry
evidence that myoepithelial cell types were changed by manipu-
lation of FoxM1, GATA3, or Rb. Based on the observed delay in
the development of the lobuloalveolar structures, we speculate
that the FoxM1/Rb-mediated inhibition of luminal differentiation
might be important for alveolar cell differentiation. In that regard,
it is noteworthy that loss of Rb in p107/ background was
shown to exhibit defective lobuloavleoli with a lactation defi-
ciency (Jiang et al., 2010). Also, virgin mice expressing a consti-
tutively active form of Rb in the mammary gland undergo prema-
ture alveolar differentiation as evidenced by staining for markers
of pregnancy (Jiang and Zacksenhaus, 2002). One intriguing
possibility is that the FoxM1/Rb complex, directly or indirectly,
promotes alveolar differentiation. Clearly, further analysis of the
mechanism by which FoxM1 participates in alveolar differentia-
tion during pregnancy is needed to establish such a model.
Rb is considered a tumor suppressor and is mutated or func-
tionally inactivated in a subset of tumors. We provide evidence
that the FoxM1/Rb complex can inhibit GATA-3 in twomammary
tumor cell lines (MDA-MB-453 and MCF7). In MCF7, we show
that the repression of GATA-3 by FoxM1 requires Rb. These
observations suggest that the pathway is active only in tumors
with functional Rb. Mutation or loss of Rb expression has been
detected in about 20 to 30%of breast cancers (Bosco and Knud-
sen, 2007; Knudsen and Knudsen, 2008). Moreover, cyclin D1 is
overexpressed in about 50% of breast cancers (Arnold and
Papanikolaou, 2005; Hollestelle et al., 2010). Because cyclin
D1 phosphorylates and inactivates Rb, it is assumed that Rb is
inactive in cyclin D1 overexpressing cases. A recent study inves-
tigated the functionality of Rb in breast cancers by looking at an
Rb loss of function gene expression signature (Ertel et al., 2010).
That study observed only a modest correlation between cyclin
D1 overexpression and Rb inactivation. Therefore, it is likely
that, despite cyclin D1 overexpression, the Rb pathway is
functional in a significant number of cases. Our observations
suggest that the FoxM1-mediated repression of GATA-3 may
not occur in either basal type harboring Rb mutations or luminal
tumors with functional inactivation of Rb. Consistent with that
FoxM1 did not inhibit GATA3 expression in the Rb mutant cellCell Reports 1, 715–729, June 28, 2012 ª2012 The Authors 725
Figure 7. Methylation by FoxM1 Is Rb Dependent
(A) Tet-off shRNA cell lines were either treated with doxycycline or vehicle for 14 days. Control or FoxM1 constructs were transfected into lines expressing Rb or
where Rb was silenced by shRNA. RT-PCR of GATA-3 expression is shown normalized to GAPDH *p < 0.05 **p < 0.001.
(B) Cells were transfected with control or FoxM1 targeting siRNA. After 72 hr, cells were collected and fixed for ChIP assay. IgG or Rb antibody was used for
immunoprecipitation. RT-PCR of Rb binding to the GATA-3 promoter is shown *p < 0.05 **p < 104.
(C) Tet-off shRNA cell lines were used for methylation specific PCR analysis of the GATA-3 promoter in the presence and absence of FoxM1 expression *p < 105,
**p < 0.01, ***p < 103.
(D) Flow cytometry of stem cells, luminal progenitors, and differentiated cells from mice expressing scrambled shRNA, Rb-targeting shRNA, FoxM1, or both
FoxM1 and Rb-targeting shRNA. Panel to the right shows semiquantitative RT-PCR of FoxM1, GATA-3 and Rb expression. Cyclophilin is shown as a loading
control *p < 104 **p < 0.01.line MDA-MB-468 (Figure S8). Given our findings, it is likely that
FoxM1 overexpression would drive accumulation of undifferen-
tiated tumor cells in a subset of luminal tumors that possess726 Cell Reports 1, 715–729, June 28, 2012 ª2012 The Authorsfunctional Rb. It is possible that overexpression of FoxM1 in
luminal progenitors, in association with other changes, promotes
the development of poorly differentiated mammary tumors.
FoxM1 expression is elevated in all tumor types examined
(Pilarsky et al., 2004). A considerable amount of work has gone
into understanding the selective advantage FoxM1 provides
tumor cells at the various steps of the cancer progression.
FoxM1 stimulates expression of several cell cycle genes, and
thus, supports the highly proliferative nature of tumor cells
(Costa, 2005). Moreover, elevated FoxM1 promotes tumor
metastasis, cell survival, and a drug resistant phenotype (Kwok
et al., 2010; Carr et al., 2010; Park et al., 2011). The results
presented here implicate another role for FoxM1 in tumor devel-




All animal experiments were preapproved by the UIC institutional animal care
and use committee. WAP-rtTA-Cre mice were obtained from the Mouse
Repository, NCI-Frederick. FoxM1 FL/FL mice have been previously charac-
terized (Wang et al., 2005). C57BL/6 and WAP-Cre mice were purchased
from Charles River Laboratories. For deletion studies, mice were given
2 mg/ml of doxycyline (Sigma) dissolved in 5% sucrose (Sigma) solution in
water bottles. A detailed description of the in vivo overexpression system
and flow cytometry analysis is provided in supplemental methods.
Bioinformatics and Statistical Analysis
Oncomine (Compendia Bioscience, Ann Arbor, MI) was used for analysis and
visualization. To analyze the expression of FoxM1 andGATA-3 in human tumor
arrays, breast cancer data sets were exported from Oncomine. Box plots are
used to show fold-change of FoxM1 expression in each tumor grade subset.
Human tissue arrays were scored by two independent pathologists. All
p values were calculated using the Student’s t test. Standard deviation of
each experiment is shown using error bars in column graphs.
Cell Culture, Constructs, and Transfections
MDA-MB-453 and MCF7 cell lines were obtained from American Type Culture
Collection (ATCC). FoxM1-pcDNA3.1 was generated by PCR amplification
and cloned into pcDNA3.1 followed by sequencing. Myc-tagged DNMT3a
and 3b were a kind gift of Frederic Chedin. Retroviral scrambled shRNA and
Rb or GATA3 shRNA constructs were purchased from Origene. Plasmid
transfection was done using Fugene 6 (Roche). Control siRNA as well as
siRNA specific to FoxM1 (Dharmacon) was transfected using Lipofectamine
(Invitrogen). For Rb knockdown studies, a doxycycline inducible shRNA
system in MCF7 cells was used and described in detail in Extended Experi-
mental Procedures.
RT-PCR and Western Blot
RNA was Trizol extracted (Invitrogen) and cDNA was synthesized by reverse
transcriptase (Bio-Rad). cDNA was amplified using SYBR Green mastermix
(Bio-Rad) and analyzed via iCycler software and the delta-delta Ct method.
All primer sequences are shown in Table S1. Protein extracts from tissue
were homogenized in lysis buffer containing: 50 mM HEPES-KOH, 300 mM
NaCl, 1mMEDTA, 1mMEGTA, 1mMDTT, 0.1%Tween 20, and 10%glycerol.
Phosphate inhibitor cocktail set II (Calbiochem) and protease inhibitor (Roche)
were added to lysis buffers before each experiment. All reagents are from
Sigma-Aldrich unless otherwise noted.
Immunohistochemistry and In Situ Hybridization
For immunohistochemistry, glands were fixed in modified Davidson’s fixative
for 48 hr, rinsed in PBS, left in 10% PBS buffered formalin overnight and
embedded in paraffin. For staining, antigen retrieval was done using sodium
citrate buffer and antibodies were incubated overnight. Antibody information
can be found in Table S2. Visualization was done using DAB and counter-
stained using Hematoxylin (Polyscientific). For antibodies of mouse origin,
mouse on mouse (MOM) kit was used. All reagents are from Vector Labsunless otherwise indicated. For in situ hybridization, T7 polymerase (Ambion)
and DIG labeled nucleotides (Roche) were used to make labeled RNA
probes (sequences can be found in Table S1). Labeling of paraffin embedded
sections was performed using IsHyb in situ hybridization kit (Biochain).
Sections were counterstained in nuclear fast red (Vector Labs) or fixed briefly
in paraformaldehyde and stained using antibodies to smooth muscle actin or
cytokeratin 18 as indicated.Whole-Mount Imaging
For carmine alum whole-mount staining, glands were removed, spread on
glass slides and placed in Carnoy’s fixative overnight. Glands were hydrated
in an alcohol gradient and left in carmine alum (Sigma) overnight then cleared
in xylene. For GFP imaging, glands were removed, spread on a glass slide,
fixed in 4% paraformaldehyde overnight, cleared in 50% glycerol in PBS for
4 hr, 75% glycerol for 4 hr, and 100% glycerol overnight. Glands were imaged
using a fluorescent dissecting scope.Chromatin Immunoprecipitation
Cells were fixed in 1% formaldehyde for 10 min to allow crosslinking and
then quenched with 125nM glycine. For in vivo chromatin immunoprecipita-
tion (ChIP) single cell suspensions were generated using collagenase/
hyaluronidase and then fixed. Cells were collected and lysed in SDS lysis
buffer. Lysate was sonicated, pre-cleared, incubated with antibodies, and
collected with Protein-A and Protein-G sepharose beads with salmon sperm
(Upstate). Beads were washed and DNA was extracted using a PCR purifica-
tion kit (QIAGEN). PCR products were visualized on a gel or analyzed using
SYBR Green (Bio-Rad) and normalized to the IgG control (Santa Cruz) as
indicated. PCR sequences and antibody information are provided in Tables
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